Table.
Demographics and outcomes of cases of SARS-CoV-2 infection with B.1.1.7 variant compared with non-B.1.1.7 variants
| n | Infection with B.1.1.7 variant | n | Infection with a non-B.1.1.7 variant | p value | ||
|---|---|---|---|---|---|---|
| Date of first positive PCR swab | 30 | Dec 3–20, 2020 | 30 | Oct 10–Dec 20, 2020 | .. | |
| Age (years) | 30 | 77 (59–88) | 30 | 79 (59–87) | 0·976 | |
| Sex | 30 | .. | 30 | .. | 0·436 | |
| Male | .. | 15 (50%) | .. | 18 (60%) | .. | |
| Female | .. | 15 (50%) | .. | 12 (40%) | .. | |
| Number of comorbidities | 30 | 2 (1–3) | 30 | 2 (1–3) | 0·845 | |
| White ethnicity (%) | 30 | 26 (87%) | 30 | 30 (100%) | 0·112 | |
| NEWS2* | 30 | .. | 30 | .. | .. | |
| At presentation | .. | 4 (2–7) | .. | 2·5 (1–6) | 0·135 | |
| Maximum value | .. | 6 (4–8) | .. | 5 (3–9) | 0·345 | |
| Respiratory rate oxygenation index | .. | .. | .. | .. | .. | |
| At presentation | 30 | 20 (15–26) | 30 | 24 (15–27) | 0·371 | |
| At maximum FiO2 | 25 | 15 (11–21) | 26 | 18 (13–26) | 0.341 | |
| Sequential Organ Failure Assessment score | 30 | .. | 30 | .. | .. | |
| At presentation | .. | 3·0 (2–7) | .. | 3·5 (2–6) | 0·858 | |
| At maximum FiO2 | .. | 5·5 (2–7) | .. | 5·0 (2–7) | 0·566 | |
| 4C Mortality Score | 30 | .. | 30 | .. | .. | |
| At presentation | .. | 12·0 (9·0–14·8) | .. | 10·5 (9·0–14·0) | 0·568 | |
| At maximum FiO2 | .. | 12·5 (8·3–14·0) | .. | 11·5 (9·0–13·0) | 0·463 | |
| Maximum ventilatory support received | 30 | .. | 30 | .. | 0·265 | |
| Mechanical ventilation | .. | 3 (10%) | .. | 1 (3%) | .. | |
| Non-invasive ventilation | .. | 0 (0%) | .. | 1 (3%) | .. | |
| Standard oxygen therapy | .. | 18 (60%) | .. | 14 (47%) | .. | |
| No supplemental oxygen required | .. | 9 (30%) | .. | 14 (47%) | .. | |
| Treatment | .. | .. | .. | .. | .. | |
| Dexamethasone | 18 | 13 (72%) | 24 | 10 (42%) | 0·049 | |
| Remdesivir | 14 | 2 (14%) | 22 | 1 (5%) | 0·547 | |
| Anticoagulation | 24 | 4 (17%) | 30 | 8 (27%) | 0·380 | |
| Tocilizumab | 28 | 1 (4%) | 28 | 0 (0%) | 1·000 | |
| 28-day mortality (%, 95% CI) | 28 | 9 (32·1%, 17·9–50·7) | 29 | 6 (20·7%, 9·8–38·4) | 0·326 | |
| Patients with a severe clinical outcome† | 30 | 11 (37%) | 30 | 8 (27%) | 0·405 | |
Data are n (%) or median (IQR), unless otherwise stated. FiO2=fraction of inspired oxygen.
*
NEWS=National Early Warning Score. *The NEWS2 score was not calculated at maximum FiO2.
†
A severe clinical outcome was defined as a WHO scale score by day 14 after symptom onset or the first positive SARS-CoV-2 PCR of at least 6 or death within 28 days.